Jim Mullen won a $20M op­tion pack­age when he switched from chair­man to the CEO job at Ed­i­tas — and it's all tied to per­for­mance

The last time James Mullen ran a bio­phar­ma com­pa­ny, he was roast­ed by Carl Ic­ahn for draw­ing tens of mil­lions of dol­lars in com­pen­sa­tion at a time Bio­gen’s stock was go­ing down.

This time, he’s start­ing back at the helm with a com­pen­sa­tion pack­age tied to suc­cess. And it’s a po­ten­tial­ly hefty one, for a biotech com­pa­ny.

Ac­cord­ing to an SEC fil­ing that dropped sev­er­al days af­ter Mullen moved from chair­man of Ed­i­tas to the CEO post of the gene edit­ing pi­o­neer, Mullen’s em­ploy­ment let­ter — which we won’t get to see un­til the 10-K drops — in­cludes op­tions of $20 mil­lion in com­pa­ny stock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER